Form 4: Penumbra CEO Exercises Options and Sells Shares Under Pre-Arranged Plan

Penumbra Inc.'s CEO and President, Adam Elsesser, exercised stock options and subsequently sold a portion of the acquired shares to cover exercise costs and tax obligations, as detailed in a recent SEC Form 4 filing.

Summary

• Adam Elsesser, CEO and President of Penumbra Inc. (PEN), exercised 27,976 stock options at an exercise price of $30.00 per share on June 11, 2025.
• Concurrently, Mr. Elsesser sold a total of 15,910 shares of Penumbra common stock through multiple transactions on the same date.
• These sales were executed at weighted average prices ranging from $251.19 to $255.73 per share.
• The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan.
• The primary purpose of the sales was to cover the exercise price of the stock options and satisfy tax withholding obligations associated with the exercise.
• Following these transactions, Mr. Elsesser directly holds 110,355 shares of common stock.
• Additionally, 577,582 shares are indirectly held by the Siegel/Elsesser Revocable Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there is insider selling, it is explicitly stated to be for tax and exercise cost purposes under a pre-arranged 10b5-1 plan, which mitigates negative interpretations. The exercise of options at a low price is a positive for the insider.

Positives

• The exercise of 27,976 stock options at a low exercise price of $30.00 indicates a significant unrealized gain for the CEO.
• The sale of shares at prices ranging from $251.19 to $255.73 demonstrates the CEO's ability to monetize a portion of his equity holdings at a high market value.
• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned activity rather than a discretionary sale based on new, non-public information.

Negatives

• The sale of 15,910 shares by a key executive, even if pre-planned, represents a reduction in direct insider ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
• The Reporting Person entered into the Rule 10b5-1 trading plan in connection with the expiration of certain stock options held by the Reporting Person and related sales of shares to satisfy the exercise price and tax withholding obligations upon the exercise of such stock options.

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive dynamics within the medical device or healthcare sector where Penumbra operates.

Related Party Transactions

• 577,582 shares are indirectly held by the Siegel/Elsesser Revocable Trust, indicating a related party holding.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO is a routine transaction under a pre-arranged plan and is unlikely to have a significant direct impact on the company's operations or strategic direction. It may slightly increase the float of shares available in the market.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

Penumbra Inc., PEN, Adam Elsesser, CEO, Stock Options, Insider Trading, Form 4, Rule 10b5-1 Plan, Share Sale, Equity Compensation